Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:07:19.902Z.
Calculation as of: 2026-10-06T15:07:19.902Z.
Quote observation: 2026-10-06T15:05:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a391670e5a4a022aad0cee8204cefb21b4613c0a4e77d467850b61b24c11a6b7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Korsana Biosciences, Inc.
Market Cap
$145.68M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.54M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$142.15M
Price/OCF Ratio
111.32
TTM Avg
51.49
3Y Avg
30.98
5Y Avg
26.48
Market Cap
$139.73M
Price/OCF Ratio
1.11
TTM Avg
4.90
3Y Avg
4.90
5Y Avg
4.90
Market Cap
$150.59M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.52M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korsana Biosciences, Inc. (KRSA) | $145.68M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $145.39M | N/A | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $142.60M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 111.32 | 51.49 | 30.98 | 26.48 |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 1.11 | 4.90 | 4.90 | 4.90 |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.59M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $153.31M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
